Harvard Bioscience Inc (HBIO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$8.02+0.25%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · HBIO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 87.8 | 86.6 | 94.1 | 112.3 | 113.3 | 118.9 | 102.1 | 116.2 | 120.8 | 77.4 | 104.5 | 108.7 | 108.7 | 105.2 | 111.2 | 108.9 |
| Total Revenues | — | — | — | — | — | — | — | 116.2 | 120.8 | 77.4 | 104.5 | 108.7 | 108.7 | 105.2 | 111.2 | 108.9 |
| Cost of Revenues | 36.7 | 36.6 | 39.4 | 46.2 | 52.5 | 51.3 | 44.1 | 51.9 | 57.6 | 38.2 | 56.1 | 59.9 | 59.3 | 57.5 | 58.8 | 58.7 |
| Gross Profit | 51.1 | 49.9 | 54.8 | 66.1 | 60.8 | 67.7 | 58.0 | 64.3 | 63.2 | 39.2 | 48.4 | 48.7 | 49.3 | 47.7 | 52.3 | 50.2 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 9.1 | 8.8 | 10.4 | 11.8 | 12.3 | 10.8 | 8.7 | 10.7 | 11.0 | 5.6 | 5.4 | 6.4 | 4.9 | 4.2 | 4.3 | 3.9 |
| Operating Income | (0.2) | (48.6) | (6.2) | 1.9 | (6.9) | 2.1 | 0.2 | 0.4 | 1.0 | (0.6) | (3.0) | (1.7) | 6.6 | 1.5 | 7.8 | 8.4 |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | 5.4 | 0.7 | 0.6 | 0.8 | 1.0 | 1.0 | 0.6 | 0.8 |
| Other Non-Operating Income / Expenses | (10.3) | (8.8) | (5.5) | (4.5) | (2.2) | (2.2) | (7.5) | (5.9) | (9.0) | (2.0) | (0.1) | (1.9) | (2.2) | (1.1) | (0.9) | (1.5) |
| Asset Writedown | — | — | — | — | — | — | 0.0 | 1.5 | — | 0.0 | 0.7 | — | — | — | — | — |
| EBT, Incl. Unusual Items | (10.5) | (57.4) | (11.7) | (2.6) | (9.2) | (0.1) | (7.3) | (5.5) | (8.0) | (2.6) | (3.1) | (3.6) | 4.4 | 0.4 | 6.9 | 6.9 |
| Income Tax Expense | (0.1) | (0.7) | 0.7 | 0.9 | 0.3 | 0.1 | 0.5 | (0.8) | (3.7) | (0.6) | 1.2 | 15.4 | 2.1 | (0.3) | 2.4 | 1.6 |
| Net Income | ||||||||||||||||
| Net Income | (10.4) | (56.7) | (12.4) | (3.4) | (9.5) | (0.3) | (7.8) | (4.7) | (2.9) | (0.9) | (4.3) | (19.0) | 2.4 | (1.8) | 2.4 | 3.8 |
| Per Share | ||||||||||||||||
| Basic EPS | (2.30) | (1.28) | (0.28) | (0.08) | (0.23) | (0.01) | — | (0.12) | (0.08) | (0.02) | (0.13) | (0.57) | 0.07 | (0.06) | 0.09 | 0.14 |
| Diluted EPS | (2.30) | (1.28) | (0.28) | (0.08) | (0.23) | — | — | (0.12) | (0.08) | (0.02) | (0.13) | (0.57) | 0.07 | (0.06) | 0.08 | 0.13 |
| Revenue per Share | 19.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 4.5 | 44.4 | 43.5 | 42.4 | 41.4 | 40.3 | 38.6 | 37.8 | 36.5 | 34.8 | 34.2 | 33.6 | 32.2 | 30.4 | 28.8 | 28.5 |
| Diluted Weighted Avg Shares | 4.5 | 44.4 | 43.5 | 42.4 | 41.4 | 40.3 | 38.6 | 37.8 | 36.5 | 34.8 | 34.2 | 33.6 | 33.2 | 31.9 | 29.8 | 29.8 |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 12.0 | — |
| EBIT | (0.2) | (48.6) | (6.2) | 1.9 | (6.9) | 2.1 | 0.2 | 0.4 | 1.0 | (0.6) | (3.0) | (1.7) | 6.6 | 1.5 | 7.8 | 8.4 |
| Effective Tax Rate | 1.2% | — | — | -33.6% | -3.7% | -105.7% | -7.1% | 14.8% | 46.1% | 23.1% | -39.9% | -427.7% | 46.7% | -66.2% | 34.8% | 23.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.